Petrelintide vs Eloralintide

    Petrelintide (ZP8396) and Eloralintide (LY3841136) are the two newest once-weekly amylin compounds in obesity research. Both reported Phase 2 results in the last year. This page compares them as research compounds.

    Development code
    ZP8396LY3841136
    Molecule
    Long-acting amylin analogueSelective amylin receptor agonist
    Administration in trials
    Once weekly subcutaneousOnce weekly subcutaneous
    Phase 2 result
    Up to 10.7% at 42 weeks (placebo 1.7%)9.5% to 20.1% at 48 weeks (placebo 0.4%)
    Stopped for side effects
    4.8% (placebo 4.9%)More GI effects at higher doses
    Next readout
    ZUPREME-2 (type 2 diabetes), second half of 2026ENLIGHTEN Phase 3 under way
    Peptx availability
    Not stocked, waitlist on its profileFactory Direct kits; UK single vials on waitlist

    Same hormone, different design goals

    Both compounds mimic amylin, the hormone released with insulin that acts in the hindbrain on satiety and meal size. Native amylin clumps into fibrils, so every analogue in this class is engineered for stability and a once-weekly half-life.

    Petrelintide is described as a long-acting amylin analogue built for high chemical and physical stability at neutral pH, and eloralintide as a selective amylin receptor agonist. Petrelintide's results lead on tolerability; eloralintide's lead on the size of the weight reduction.

    What the Phase 2 trials show

    Results reported in March 2026 showed petrelintide reaching up to 10.7% mean weight reduction at 42 weeks in the ZUPREME-1 trial, against 1.7% with placebo. Discontinuations for side effects were 4.8%, against 4.9% on placebo, and the most effective arm had no vomiting.

    Eloralintide's Phase 2, published in The Lancet in November 2025, reached 9.5% to 20.1% at 48 weeks across its dose arms, against 0.4% with placebo. The trials differ in length, population and dosing, so the figures are not a head-to-head comparison.

    Where each programme goes next

    Petrelintide's second Phase 2 trial, ZUPREME-2 in people with type 2 diabetes, is due to report in the second half of 2026, the Phase 3 ZUPREME programme started at the end of September 2026, and a Phase 2 study combining it with the incretin candidate CT-388 is planned. Eloralintide is in the ENLIGHTEN Phase 3 programme, and its combination with tirzepatide reported a 48-week Phase 2b in September 2026.

    Bottom line for research labs

    Petrelintide and Eloralintide are the two amylin compounds to watch, and both are now in Phase 3. Eloralintide has the larger published Phase 2 effect; Petrelintide has the cleaner tolerability story, with its type 2 diabetes Phase 2 still to report. For amylin receptor research today, Eloralintide is the better documented of the two.

    Frequently asked questions

    Are Petrelintide and Eloralintide the same kind of compound?▼
    Both are once-weekly, amylin-based investigational compounds for obesity research. They differ in design: petrelintide is a long-acting amylin analogue, eloralintide a selective amylin receptor agonist.
    Which produced more weight reduction?▼
    In separate Phase 2 trials, Eloralintide's top arms reached about 20% at 48 weeks and Petrelintide reached 10.7% at 42 weeks. The trials were not head to head and differ in design, so this is not a reliable ranking. Petrelintide's results put more weight on tolerability.
    How do they compare with Cagrilintide?▼
    Cagrilintide is an earlier long-acting amylin analogue, best known in combination with semaglutide. It acts on both amylin and calcitonin receptors. The Eloralintide vs Cagrilintide page covers that comparison.
    Can I buy them from Peptx?▼
    Petrelintide is not stocked; its profile page has a waitlist. Eloralintide Factory Direct kits are available now. UK single vials are out of stock for now; join the waitlist on this page and we will email you when the next stock lands. Both are investigational compounds for in-vitro research only.